Tirzepatide (10mg/vial)

Tirzepatide is a dual GLP-1 and GIP receptor agonist designed to support weight management and improve metabolic health. By activating both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, Tirzepatide helps regulate appetite, slow gastric emptying, enhance feelings of fullness, and improve insulin sensitivity. This dual mechanism has made it one of the most effective therapies currently available for obesity and type 2 diabetes. 

Large clinical trials have demonstrated that Tirzepatide can produce substantial and sustained reductions in body weight when combined with lifestyle modifications. Research has also shown improvements in blood glucose control, cardiovascular risk factors, and several markers of metabolic health. In people with obesity, participants in clinical studies achieved average weight reductions exceeding 20% at higher doses, making Tirzepatide one of the most effective pharmacologic options studied for chronic weight management.

Tirzepatide is approved by Health Canada and the U.S. FDA for the treatment of type 2 diabetes and chronic weight management in eligible adults under specific brand names. It should be used under the supervision of a qualified healthcare professional and as part of a comprehensive approach that includes nutrition, physical activity, and long-term lifestyle changes.